Study of CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent Glioblastoma
This is a single-center, open-label, dose-range finding Phase I study of hP1A8, a new adjuvant CD200 activation receptor ligand (CD200AR-L), in combination with imiquimod and the GBM6-AD vaccine to treat recurrent glioblastoma (GBM) in adults.
Glioblastoma
DRUG: Treatment with hP1A8
Maximum tolerated dose (MTD) of hP1A8 when administered with imiquimod and GBM6-AD, 12 months
Incidence of serious adverse events (SAEs), 12 months|Time to progression (TTP), 24 months|Progression free survival (PFS), 24 months|Overall survival (OS), 24 months
This is a single-center, open-label, dose-range finding Phase I study of hP1A8, a new adjuvant CD200 activation receptor ligand (CD200AR-L), in combination with imiquimod and the GBM6-AD vaccine to treat recurrent glioblastoma (GBM) in adults.